Amicus Therapeutics (FOLD) Downgraded by BidaskClub to Sell

BidaskClub cut shares of Amicus Therapeutics (NASDAQ:FOLD) from a hold rating to a sell rating in a research report released on Tuesday morning, BidAskClub reports.

A number of other analysts have also commented on the company. Robert W. Baird set a $20.00 target price on Amicus Therapeutics and gave the company a buy rating in a research report on Monday. Janney Montgomery Scott assumed coverage on Amicus Therapeutics in a research report on Friday, April 5th. They issued a buy rating and a $13.91 target price for the company. ValuEngine raised Amicus Therapeutics from a hold rating to a buy rating in a research report on Friday, March 1st. Cantor Fitzgerald reaffirmed a buy rating and issued a $20.00 target price on shares of Amicus Therapeutics in a research report on Tuesday, February 26th. Finally, Zacks Investment Research raised Amicus Therapeutics from a sell rating to a hold rating in a research report on Monday, February 4th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $18.19.

FOLD stock opened at $13.29 on Tuesday. Amicus Therapeutics has a 1-year low of $8.27 and a 1-year high of $17.62. The company has a debt-to-equity ratio of 0.94, a current ratio of 6.40 and a quick ratio of 6.30. The stock has a market capitalization of $2.97 billion, a PE ratio of -9.99 and a beta of 1.85.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Thursday, February 28th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.13). Amicus Therapeutics had a negative net margin of 382.48% and a negative return on equity of 54.21%. The firm had revenue of $32.64 million during the quarter, compared to the consensus estimate of $30.81 million. During the same period in the previous year, the firm earned ($0.41) earnings per share. The business’s quarterly revenue was up 121.6% on a year-over-year basis. Analysts expect that Amicus Therapeutics will post -1.08 earnings per share for the current year.

In other Amicus Therapeutics news, CEO John F. Crowley sold 20,000 shares of Amicus Therapeutics stock in a transaction dated Friday, February 1st. The stock was sold at an average price of $12.12, for a total transaction of $242,400.00. Following the completion of the transaction, the chief executive officer now owns 688,081 shares in the company, valued at approximately $8,339,541.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jay Barth sold 50,000 shares of Amicus Therapeutics stock in a transaction dated Friday, April 5th. The shares were sold at an average price of $14.20, for a total value of $710,000.00. Following the transaction, the insider now owns 179,767 shares of the company’s stock, valued at approximately $2,552,691.40. The disclosure for this sale can be found here. Insiders sold a total of 180,000 shares of company stock valued at $2,373,400 over the last ninety days. 2.90% of the stock is currently owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the business. Marshall Wace LLP acquired a new position in Amicus Therapeutics during the 3rd quarter valued at about $14,096,000. Man Group plc boosted its stake in Amicus Therapeutics by 469.2% during the 3rd quarter. Man Group plc now owns 218,786 shares of the biopharmaceutical company’s stock valued at $2,645,000 after purchasing an additional 180,351 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Amicus Therapeutics by 3.3% in the 3rd quarter. Vanguard Group Inc. now owns 16,807,772 shares of the biopharmaceutical company’s stock worth $203,205,000 after buying an additional 541,308 shares during the last quarter. Sofinnova Investments Inc. boosted its stake in shares of Amicus Therapeutics by 51.3% in the 4th quarter. Sofinnova Investments Inc. now owns 674,636 shares of the biopharmaceutical company’s stock worth $6,462,000 after buying an additional 228,667 shares during the last quarter. Finally, MetLife Investment Advisors LLC boosted its stake in shares of Amicus Therapeutics by 55.5% in the 3rd quarter. MetLife Investment Advisors LLC now owns 133,286 shares of the biopharmaceutical company’s stock worth $1,611,000 after buying an additional 47,562 shares during the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Featured Story: What is the Quick Ratio?

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.